Abstract
Now that national guidelines recommend sodium-glucose cotransporter-2 (SGLT2) inhibitors for the treatment of heart failure, pharmacists are identifying prescribing gaps and targeting patients who can benefit from the therapy. At NYC Health + Hospitals/Kings County in Brooklyn, NY, just 23 patients who were admitted for heart failure—or for ischemic stroke with type 2 diabetes—received a discharge prescription for an SGLT2 inhibitor in 2021, said Shireen Farzadeh, transitions of care clinical pharmacist at the a639-bed public teaching hospital. Last year, in response to updated heart failure guidelines from the American College of Cardiology (ACC), American Heart Association (AHA), and Heart Failure Society of America (HFSA) and revised diabetes management guidelines from the American Diabetes Association (ADA), the hospital launched a pharmacist-led service to boost discharge prescribing of the SGLT2 inhibitor empagliflozin. The results were dramatic. From April through August 2022, 110 patients who were admitted with heart failure or ischemic stroke with type 2 diabetes were discharged with a supply of empagliflozin or a prescription for it.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
